RD133 for mesothelin-positive tumors after prior treatments
Part of Cancer clinical trials.
This early-phase study tests RD133, an experimental treatment, in adults whose solid tumors are mesothelin-positive and have come back or not responded to prior standard therapies. It aims to see how well RD133 can control these cancers and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and sign an informed consent form before any study steps
- Have already tried at least 2 standard treatments, and the last one did not work
- Your tumor must test “mesothelin-positive” on the cancer cell surface in lab testing (over 25% of tumor cells)
- Have scans showing at least one measurable tumor spot that can be followed, and expect to live at least 12 weeks
- Have enough blood counts and organ function based on lab tests (neutrophils, platelets, hemoglobin, liver and kidney tests)
- Have heart ultrasound showing adequate pumping (ejection fraction ≥ 50%) and enough oxygen levels; also meet basic clotting test ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SY001, which targets a protein called mesothelin found on some cancer cells. It is designed for people with advanced ovarian or pancreatic cancer who have already tried other treatments and whose tumor tissue has mesothelin.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
This study tests a new drug called RC288 to treat solid tumors (cancers that form lumps). Researchers want to see if it's safe and how well it works for people whose cancer hasn't responded to other treatments or has returned.
This early-stage trial tests whether RD133 can be safe and effective for people whose solid tumors have a high “mesothelin” marker and that have not responded to at least two standard treatments. If you qualify, you’ll be checked closely for side effects and whether the tumor responds.
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and attack cancer cells showing a protein called mesothelin. It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.